IN2012DN03172A - - Google Patents

Download PDF

Info

Publication number
IN2012DN03172A
IN2012DN03172A IN3172DEN2012A IN2012DN03172A IN 2012DN03172 A IN2012DN03172 A IN 2012DN03172A IN 3172DEN2012 A IN3172DEN2012 A IN 3172DEN2012A IN 2012DN03172 A IN2012DN03172 A IN 2012DN03172A
Authority
IN
India
Prior art keywords
dose
human patient
antibody
dosage regimen
present
Prior art date
Application number
Other languages
English (en)
Inventor
Gerhard Zugmeier
Peter Kufer
Dominik Ruttinger
Sabine Kaubitzsch
Original Assignee
Micromet Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Micromet Ag filed Critical Micromet Ag
Publication of IN2012DN03172A publication Critical patent/IN2012DN03172A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39541—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against normal tissues, cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Biochemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Animal Behavior & Ethology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Veterinary Medicine (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Cell Biology (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
IN3172DEN2012 2009-09-18 2010-09-20 IN2012DN03172A (fr)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US24365109P 2009-09-18 2009-09-18
EP09170715 2009-09-18
US34414710P 2010-06-01 2010-06-01
EP10164596 2010-06-01
PCT/EP2010/063795 WO2011033105A1 (fr) 2009-09-18 2010-09-20 Régime posologique pour l'administration d'un anticorps bispécifique epcamxcd3

Publications (1)

Publication Number Publication Date
IN2012DN03172A true IN2012DN03172A (fr) 2015-09-25

Family

ID=43127167

Family Applications (1)

Application Number Title Priority Date Filing Date
IN3172DEN2012 IN2012DN03172A (fr) 2009-09-18 2010-09-20

Country Status (15)

Country Link
US (1) US20120244161A1 (fr)
EP (1) EP2477653A1 (fr)
JP (1) JP2013505223A (fr)
KR (1) KR20120083359A (fr)
CN (1) CN102711825A (fr)
AU (1) AU2010297258A1 (fr)
BR (1) BR112012008345A2 (fr)
CA (1) CA2774732A1 (fr)
IL (1) IL218637A0 (fr)
IN (1) IN2012DN03172A (fr)
MX (1) MX2012003175A (fr)
NZ (1) NZ598601A (fr)
RU (1) RU2012115480A (fr)
SG (2) SG10201405434VA (fr)
WO (1) WO2011033105A1 (fr)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6400470B2 (ja) * 2011-05-16 2018-10-03 ジェネロン（シャンハイ）コーポレイション リミテッド 多重特異性Ｆａｂ融合タンパク質および使用法
AR089114A1 (es) 2011-12-09 2014-07-30 Amgen Res Munich Gmbh PREVENCION DE LOS EFECTOS ADVERSOS CAUSADOS POR LOS ANTICUERPOS BIESPECIFICOS EpCAMxCD3
GB201302447D0 (en) 2013-02-12 2013-03-27 Oxford Biotherapeutics Ltd Therapeutic and diagnostic target
US10370431B2 (en) 2013-02-15 2019-08-06 Bioverativ Therapeutics Inc. Optimized factor VIII gene
EP2961773B1 (fr) * 2013-02-26 2019-03-20 Roche Glycart AG Molécules bispécifiques de liaison à l'antigène activant les lymphocytes t
AU2015204766B2 (en) * 2014-01-08 2020-08-13 The Board Of Trustees Of The Leland Stanford Junior University Targeted therapy for small cell lung cancer
US11008561B2 (en) 2014-06-30 2021-05-18 Bioverativ Therapeutics Inc. Optimized factor IX gene
IL319047A (en) * 2015-08-28 2025-04-01 Amunix Operating Inc Chimeric polypeptide composition and methods for its preparation and use
ES2873846T5 (en) * 2015-11-19 2025-06-23 Revitope Ltd Functional antibody fragment complementation for a two-components system for redirected killing of unwanted cells
EP3411478B1 (fr) 2016-02-01 2022-06-08 Bioverativ Therapeutics Inc. Gènes du facteur viii optimisés
US12128102B2 (en) 2016-03-08 2024-10-29 Takeda Pharmaceutical Company Limited Constrained conditionally activated binding proteins
CN109476756B (zh) 2016-03-15 2022-05-31 埃泰美德(香港)有限公司 一种多特异性Fab融合蛋白及其用途
WO2017167350A1 (fr) * 2016-03-30 2017-10-05 Horst Lindhofer Anticorps multispécifiques destinés à être utilisés pour le traitement d'un néoplasme du tractus urinaire
EP3409322A1 (fr) * 2017-06-01 2018-12-05 F. Hoffmann-La Roche AG Procédés de traitement
EP3679067A2 (fr) 2017-09-08 2020-07-15 Maverick Therapeutics, Inc. Protéines de liaison à activation conditionnelle restreinte
CN112867735B (zh) 2018-09-07 2025-05-09 埃泰美德(香港)有限公司 双特异性抗原结合蛋白及其用途
WO2020132810A1 (fr) 2018-12-24 2020-07-02 Generon (Shanghai) Corporation Ltd. Protéines multispécifiques de liaison à l'antigène pouvant se lier à cd19 et cd3, et leur utilisation
CN114390938B (zh) 2019-03-05 2025-03-21 武田药品工业有限公司 受约束的条件性活化的结合蛋白
JP7803014B2 (ja) 2019-09-30 2026-01-21 バイオベラティブ セラピューティクス インコーポレイテッド レンチウイルスベクター製剤
IL299333A (en) 2020-06-24 2023-02-01 Bioverativ Therapeutics Inc Methods for the purification of viral vectors
KR20240100453A (ko) * 2021-11-19 2024-07-01 우한 이지 바이오파마 씨오., 엘티디. 이중 특이적 항체 및 이의 응용

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE243754T1 (de) 1987-05-21 2003-07-15 Micromet Ag Multifunktionelle proteine mit vorbestimmter zielsetzung
DE602004030811D1 (de) 2003-10-16 2011-02-10 Micromet Ag Multispezifische deimmunisierte cd3-bindende moleküle
CA2606081C (fr) * 2005-04-26 2013-09-17 Markus M. Heiss Combinaison d'anticorps et de glucocorticoides destinee au traitement du cancer

Also Published As

Publication number Publication date
SG179027A1 (en) 2012-04-27
KR20120083359A (ko) 2012-07-25
MX2012003175A (es) 2012-04-11
JP2013505223A (ja) 2013-02-14
US20120244161A1 (en) 2012-09-27
RU2012115480A (ru) 2013-10-27
NZ598601A (en) 2014-05-30
BR112012008345A2 (pt) 2016-08-09
SG10201405434VA (en) 2014-10-30
WO2011033105A1 (fr) 2011-03-24
CA2774732A1 (fr) 2011-03-24
EP2477653A1 (fr) 2012-07-25
AU2010297258A1 (en) 2012-03-29
IL218637A0 (en) 2012-05-31
CN102711825A (zh) 2012-10-03

Similar Documents

Publication Publication Date Title
IN2012DN03172A (fr)
NZ609201A (en) Means and methods for treating dlbcl
MX385543B (es) Uso de un anticuerpo biespecífico para tratar cáncer de linfocitos b.
MX354371B (es) Régimen de dosificación para administrar un anticuerpo biespecífico cd19xcd3 a pacientes en riesgo de efectos adversos potenciales.
SG179204A1 (en) Dosage regimen for administering a cd19xcd3 bispecific antibody
MX2011007589A (es) Tratamiento de un cancer usando una combinacion de bendamustine y un anticuerpo anti-cd20.
MX2014004548A (es) Metodos para tratar pacientes pediatricos usando dexmedetomidina.
MY173215A (en) Acetylcysteine compositions and methods of use thereof
EA201290171A1 (ru) Вводимые перорально кортикостероидные композиции
EP3501546A3 (fr) Nouveaux conjugués cystéine-principe actif et leur utilisation
EP4371615A3 (fr) Traitement de la dmla à l'aide de aav sflt-1
NZ606993A (en) Combination pharmaceutical composition and methods of treating and preventing the infectious diseases
MY159353A (en) Pirfenidone treatment for patients with atypical liver function
MX2010005631A (es) Nuevos compuestos de hidrocarburo ciclicos para el tratamiento de enfermedades.
AU2010300611A8 (en) Hematopoietic stem cells for use in the treatment of a kidney injury
RU2017134443A (ru) Способ лечения с применением традипитанта
PH12013502039B1 (en) Monoclonal antibodies against tissue factor pathway inhibitor (tfpi)
MX352647B (es) Metodo para temporizar una colonoscopia en donde se administra una composicion de picosulfato.
UA105191C2 (ru) Лечение пирфенидоном пациентов с атипической функцией печени
WO2012079093A3 (fr) Dosage et administration de conjugués scfv bispécifiques
WO2012063134A3 (fr) Analogues de glycoside cardiaque en combinaison avec l'émodine pour le traitement du cancer
IN2014DN09437A (fr)
MX2012005497A (es) Tivozanib y temsirolimus en combinacion.
UA55926U (ru) Способ лечения хронического перфоративного межкорневого периодонтита
MX2022006054A (es) Dosificacion y administracion de una vacuna de glucoconjugados de sacaridos bacterianos.